Background
When a sponsor changes clinical operations partners mid-study, the margin for error is exceptionally narrow. Timelines are compressed, institutional knowledge must transfer rapidly, and the incoming organization must absorb an established study infrastructure while simultaneously addressing the conditions that necessitated the transition. It is, by any measure, one of the most demanding scenarios in clinical research operations.
That is precisely the environment in which Worldwide Clinical Trials was engaged to take over a Phase II, randomized, double-blind, placebo-controlled multicenter study evaluating an investigational compound for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN). The sponsor, a clinical-stage neuroscience company, decided to transition the study to Worldwide during a protocol hold. This created both urgency and an opportunity to reset the program on firmer operational ground. What followed was a study that would test the organization’s agility, problem-solving capabilities, and depth of therapeutic expertise at every stage of execution.
Challenges
Taking over an active clinical study means inheriting not only its infrastructure, but its accumulated operational liabilities, and this program arrived with several.
1. Site Quality & Enrollment Rate
Site quality was the most immediately consequential issue. The sponsor had requested that Worldwide retain several sites from the original CRO’s network. Upon assessment, it became clear that these sites lacked both the appropriate patient population and the indication-specific experience the protocol demanded. Enrollment performance reflected this gap directly, and it was evident that meaningful progress would require decisive action on site composition.
2. High Screen Failure Rate
Compounding the enrollment picture was a screen failure rate that, while broadly anticipated given the DPN population (estimated at 75%), was driven by a demanding randomization algorithm, inadequate glycemic control among candidates, and the practical rigors of protocol adherence.
3. Staffing Complications
At the operational level, the study identified a confluence of challenges requiring simultaneous management. Three medical monitor changes within a single three-week period destabilized a critical safety oversight function, creating downstream complications for eligibility review, laboratory alert management, and ECG review. With 11 serious adverse events (SAEs) requiring resolution, medical monitoring meetings had become consumed by SAE management to the exclusion of their intended purpose — a structural problem that demanded a structural solution.
4. Protocol Deviation Backlog
Meanwhile, a significant backlog of protocol deviations (PDs) awaited internal review and sponsor reconciliation, representing a real risk to database lock (DBL) readiness. The central laboratory also encountered kit supply disruptions that intermittently slowed screening activity at certain sites.
5. Vendor Management
Vendor transition added another layer of complexity. Establishing new vendor contracts and fast-tracking system migrations for a study already in motion required a level of coordination that left no room for sequential thinking. Everything had to move in parallel.
Solutions
Worldwide’s response to these challenges was defined by the organizational instinct that distinguishes an experienced rescue partner from a standard CRO transition: the ability to triage problems in real time, implement structural fixes without disrupting study momentum, and maintain an unrelenting focus on data quality and milestone delivery. Essentially, we recognized the transition as a project in and of itself, which supported the clinical study’s success.
1. Site Portfolio
The site portfolio was the first priority. Rather than preserving the inherited site list out of operational inertia, Worldwide moved decisively to evaluate and replace underperforming sites with ones that had both the appropriate patient population and demonstrated experience in the indication. To manage the complexity of simultaneously closing legacy sites and activating new ones, the team developed dedicated site close-out and start-up trackers, alongside a formal transition checklist that proved instrumental in maintaining oversight across a rapidly shifting site network. The impact was direct and measurable, and once the right sites were in place, enrollment accelerated. The program, which had been projected to enroll over 12 months, was completed in 10 months, with a monthly enrollment rate of 23 subjects against a planned rate of 17.
2. Tightened Communication
To restore the integrity of the medical monitoring function, Worldwide restructured the meeting cadence. We established a combined medical monitoring and pharmacovigilance review framework that clearly separated routine eligibility and safety-alert management from SAE resolution. This structural realignment ensured that medical oversight was exercised with the rigor and focus the protocol required, rather than being perpetually consumed by reactive case management.
3. Dedicated, Purposeful Resource Deployment
The protocol deviation backlog was addressed through deliberate resource deployment. Dedicated personnel were assigned specifically to deviation entry, internal review, and sponsor reconciliation, enabling the team to systematically resolve accumulated items and achieve full review of all outstanding deviations prior to DBL. Site management introduced biweekly “PD Café” calls with individual clinical research associates, creating structured forums to address deviation-related queries within the CTMS in real time and prevent future accumulation. To ensure medical monitoring listings were DBL-ready, the team implemented a policy requiring AE review and finalization at least 10 days prior to lock, with ad hoc meetings convened for any late-breaking entries.
Laboratory disruptions at the central vendor level were mitigated through careful monitoring, extended screening window management, and flexible rescheduling of site visits. This preserved patient flow without compromising data integrity.
Outcome
Throughout all of this, the partnership between Worldwide and the sponsor remained a defining feature of the program’s execution. A relationship built on transparency, shared accountability, and mutual trust created the conditions for solving complex problems quickly and without friction.
The results spoke clearly to the quality of our delivery. All study milestones were achieved on time. Enrollment closed ahead of schedule. DBL was achieved within 6 weeks of the last patient, last visit, with the final clinical study report delivered shortly before the committed date. The sponsor was explicit in its assessment: the studies were very well run. The distinction between a drug that does not perform and a study that does is one that Worldwide is uniquely positioned to deliver, even when stepping into a program that others could not complete.
To learn more about our capabilities for transitioning and executing your clinical program, contact our team today.
